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THE EFFECTS OF GAIN OF FUNCTION MUTANT P53 AND P63 ON EPS8 AND 
CXCL5 EXPRESSION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA 
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A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University. 
Virginia Commonwealth University, 2013. 
 
Major Director:  Dr. W. Andrew Yeudall 
Associate Professor, Oral and Craniofacial Molecular Biology  
 
 
Head and neck squamous cell carcinoma (HNSCC) is one of the ten most common 
cancers worldwide, with a survival rate of less than 50%.  A class of mutant p53, known as 
gain of function (GOF) mutant p53, has been found to be expressed in tumors in these 
patients.  GOF mutant p53 not only loses the wild type tumor suppressor functions, but 
also gains aberrant functions that have been linked to tumorigenesis. In this current study, 
we utilized a model system consisting of cells derived from HNSCC tumors in order to 
investigate our hypothesis that GOF mutant p53 enhances and p63 inhibits EPS8 and 
CXCL5 expression and promoter activity.  We found decreased EPS8 expression, CXCL5 
expression, and cellular migration associated with the loss of GOF mutant p53.  This 
indicates an enhancing role of GOF mutant p53 in cellular migration and expression of 
these target genes.  The loss of GOF mutant p53 was also associated with decreased EPS8 
and CXCL5 promoter activity, indicating upregulation of these target gene promoters by 
GOF mutant p53. We found increased EPS8 expression, CXCL5 expression, and cellular 
migration with the loss of p63 in cell expressing high levels of p63. This indicates an 
   
 ix 
inhibitory role of p63 on the expression of these target genes and cellular migration.  Loss 
of p63 was also associated with increased EPS8 and CXCL5 promoter activity, indicating 
p63 may be downregulating these target gene promoters.  EPS8 and CXCL5 in 
tumorigenesis, our findings suggest that GOF mutant p53 and p63 play role in 
tumorigenesis. Additional studies are needed to further elucidate the mechanism by which 
GOF mutant p53 and p63 regulate EPS8 and CXCL5 expression and promoter activity. 
  1 
Introduction 
 
1.1 Head and Neck Squamous Cell Carcinoma 
Head and neck squamous cell carcinoma (HNSCC) encompasses cancers deriving 
from the mucosal surfaces of the head and neck including the oral cavity, pharynx, larynx, 
paranasal sinuses and nasal cavity
1
.  HNSCC is one of the ten most common cancers 
worldwide, with over 650,000 new cases reported annually.  In the United States, HNSCC 
accounts for about 3% of reported malignancies
2
.  The overall survival rate is low at 50%, 
which can be attributed to late presentation and metastatic tumor progression
3
.    
Risk factors for HNSCC include tobacco use (smoking or chewing), heavy alcohol 
use, human papilloma virus (HPV) and poor oral hygiene.  Tobacco use is a major risk 
factor due to carcinogens present causing genotoxic stress that can lead to the mutations 
and the formation of tumors.  Acetaldehyde, a metabolite of alcohol, interferes with DNA 
synthesis and repair.  The effects of alcohol are synergistic with tobacco, while heavy 
alcohol consumption is also recognized as an independent risk factor.  Oral HPV infection 
has been shown to be linked to HNSCC
2
, with evidence mounting for an etiological role of 
HPV infection, specifically the HPV E6 oncoprotein, in HNSCC
4
.  Current therapies for 
HNSCC include surgery, chemotherapy, radiation therapy, or a combination of therapies 
and treatment plans that vary by location of primary tumor and clinical stage.  HPV 
positive patients also receive differing treatment therapies than those who are HPV 
negative
1
. 
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1.2 Tumor Metastasis    
The oral cavity is lined by stratified squamous epithelia delineated by a continuous 
basement membrane.  The basement membrane regulates differentiation and migration of 
epithelial cells and also serves as a barrier to invasion during tumorigenesis (Figure 1).  
Tumors arise through progressive acquisition of genetic alterations affecting regulation of 
cell growth, motility, and stromal interactions due to exposure to carcinogens. Prior to 
invasion, abnormal cellular growth, differentiation, and stratification occurs in the 
epithelium
2
.  
 
Figure 1 Tumor Progression and Metastasis in HNSCC.  Squamous epithelium transforms 
into an invasive tumor from exposure to carcinogens.  These tumor cells stimulate 
development of their own blood supply and cellular growth and migration.  Migration and 
invasion can lead to secondary tumor growth, known as metastasis.  Modified from Philips 
Institute Webpage
5
.
 
 
Primary HNSCC tumors are aggressive locally and often metastasize to nearby 
lymph nodes and less often to distant sites
3
.  Metastasis occurs when cancer cells invade 
local tissues and move into lymph vessels or blood vessels (Figure 1).  Cancer cells are 
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able to move through the lymphatic system or bloodstream to distant sites in the body 
where they can migrate into surrounding tissues.  At distant locations, cancer cells can 
proliferate and stimulate angiogenesis
6
. Invasion and metastasis occur when tumor cells 
acquire distinct phenotypes from the primary tumor cells including increased motility, 
ability to degrade surrounding extracellular matrix (ECM), and enhanced survival.  
Cytokines and growth factors play a key role in cell migration and invasion during 
metastasis
3
.  
 
1.3 p53 
p53 is a transcription factor involved in cell cycle regulation, apoptosis, and 
angiogenesis encoded by the gene TP53.  The p53 protein binds in a sequence specific 
manner to target genes involved in growth arrest, DNA damage repair, apoptosis and 
inhibition of angiogenesis. Normally, p53 is kept at low steady state levels through an 
autoregulatory feedback loop involving Mdm2, which promotes rapid degradation of p53.  
Wild type p53 has been shown to suppress tumorigenesis and is known as a tumor 
supressor.   Mutation or loss of wild type p53 has been implicated in a variety of cancers, 
including those of the oral cavity, lung, breast, skin, and colorectal region
7
.   
Human p53 is a 393 amino acid protein with three distinct functional domains: an 
acidic N-terminal transactivation domain, a central DNA-binding domain, and a basic C-
terminal oligomerization domain. The acidic N-terminal domain is critical for p53’s 
function as a transcriptional activator and is often a site of regulation, for example by 
Mdm2
7
.  The basic C-terminal domain allows for tetramerization for functionality
8
. The 
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central DNA-binding domain (residues 100-293; Figure 2) is required for sequence 
specific DNA binding, which binds to 200-300 consensus sites in the human genome.  The 
majority of p53 mutations in human tumors occur in the central DNA binding domain and 
affect p53’s ability to bind to the wild type p53 consensus DNA sequence7. Most p53 
mutations are single base substitutions occurring within this DNA binding domain
9
.    
 
Figure 2: Model of the p53 Core Domain Tetramer DNA Complex.  
Core DNA binding domain of each p53 monomer interacts with DNA 
through its central DNA Binding domain residues 100-293
10
.
 
 
1.4 Mutant p53 
The TP53 gene is the most commonly mutated gene in HNSCC
11
, occurring in over 
50% of HNSCC patients.  TP53 mutational analysis has been used as a prognosis 
indicator
2
.  There are three major classes of mutant p53.  The first, loss of function, results 
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in a non functional p53 protein.  The second, dominant negative, results in a monomer that 
is able to tetramerize with the wild type and mask wild type function.  The third, gain of 
function, leads to p53 protein that not only loses the wild type tumor suppressor function, 
but gains new oncogenic functions
12
.    
Mutations occurring in the DNA binding domain have been correlated with poor 
prognosis in HNSCC including accelerated tumor progression and decreased patient 
survival
2
.  Previous studies have shown high levels of mutant p53 with single point 
mutations in cell lines derived from HNSCC tumors
13
.  These mutations occurring in the 
DNA binding domain lead not only to the loss of normal tumor suppressor function by 
interfering with p53’s ability to induce apoptosis, but also the gain of oncogenic functions 
leading to increased proliferative and metastatic potential.  Oncogenic functions gained 
include greater protein stability, immortalization and loss of apoptosis induced by growth 
factor removal
14
.   These gain of function (GOF) mutant p53 proteins have been shown to 
transform immortalized fibroblast NIH/3T3 cells into malignant phenotypes and even 
overcome the effects of wild type p53 if present
8
.    
Mutant p53 heteromerizes with wild type p53 when present and drives the 
formation of complexes that function aberrantly, masking wild type function.  There is a 
large spectrum of p53 mutations with different effects at varying strengths, partially based 
on location of the mutation.  These widespread effects of mutant p53 are due to the ability 
of p53 to bind to many consensus sequences within the genome
14
.  Previous studies have 
shown cells expressing GOF mutant p53 have transcriptomes different from those 
expressing wild type p53 or p53 null cells
15
.  Mutant p53-containing cells have also shown 
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elevated expression levels of genes whose protein products are critical in the regulation of 
cell cycle, transcription, cell matrix interactions, and DNA replication and repair, which 
can lead to enhanced cancer development, progression, and chemoresistance
16
.   
 
1.5 p63 
p63 is a member of a family of transcription factors that includes p53 and p73.  p63 
plays a role in stratification of epithelium during development, including the oral mucosa 
and the epidermis, and in cancer during adulthood. Inactivation of p63 is lethal in mice due 
to the lack of stratified squamous epithelia and its derivatives including appendages and 
salivary glands
17,18
.  p63 is rarely mutated in cancer and its expression has been found to be 
retained or amplified in HNSCC.  Amplified expression of p63 protein can lead to an 
altered ratio of its two isoforms (see below).  This ratio, but not necessarily the overall 
level of p63, has been suggested to determine biological outcome.
17
 
p63 has been found to be expressed in the basement membrane of stratified 
epithelial tissues and highly expressed in some cancers deriving from these tissues, 
including HNSCC
18.  p63 has two distinct isoforms, TAp63 and ΔNp63, which are 
encoded by the same gene (TP63).  These two isoforms have different promoters and 
alternative splicing patterns at the C terminus, leading to three isoforms (α,β,and γ) each 
for both TA and ΔNp63 of differing molecular weights (Figure 3) . Distinct roles and 
molecular mechanisms of p63 isoforms are still controversial. TAp63 functions in a 
transactivating manner and has been found to contribute to maintenance of dermal and 
epidermal precursors, genomic stability, and lifespan
17. ΔNp63 functions in a dominant 
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negative fashion as a transcriptional repressor
18.  During development, ΔNp63 plays a 
critical role in stratification of the epithelium.  In adulthood, ΔNp63 is required for 
maintenance of “stemness” of stem cells within the stratified epithelia,17 which are 
required for normal tissue renewal and regeneration after damage
19. ΔNp63α  has been 
found to be most prominent in the basal layers of the epithelium and the predominant 
isoform of p63 in HNSCC
20.   ΔNp63α has been found to mediate silencing of its own 
promoter in response to genomic stress.  This decreased transcription was found to lead to 
altered expression patterns of p53 target genes
21
.   
 
Figure 3: Isoforms of p63.  Both (TA)p63 and ΔNp63 are transcribed from the TP63 gene 
from different promoters and undergo alternate splicing at the C terminal leading to six 
total isoforms, which vary by molecular weight.  Modified from Barbieri,et.al. 2006 
18
 
 
 
Previous studies suggest that p63 may be binding to approximately 5800 promoters 
in the human genome, affecting 7% of the coding genes
17
.  Like other members of the p53 
family, active p63 functions as a tetramer
17
 and binds to distinct p63 consensus DNA 
binding sites
18
.  p63 has the ability to tetramerize amongst isoforms and with p53 and 
p73.
17
 p63 can also bind to p53 consensus DNA binding sites in vitro and in vivo due to its 
high sequence and structural similarity to p53.
18
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In contrast to p53, p63 is not a classical tumor suppressor, but functions primarily 
in embryonic development. Mutant p53 has been found to interact physically with p63 
resulting in loss of p63 function.  In non small cell lung cancer cells, a type of epithelial 
cancer, mutant p53 has been seen to physically interact with TAp63 and this correlated 
with inhibition of p63 function
22
.  In addition, overexpression of p63 in HNSCC is needed 
for the expression of over a hundred genes, many that are involved in cell motility
23
.   
 
1.6 Epidermal Growth Factor Receptor Signaling  
Growth factors, such as epidermal growth factor (EGF) and transforming growth 
factor-β (TGF-β), play key roles in tumor progression and metastasis.  EGF is a stimulator 
of epithelial cell growth and is capable of activating motility pathways
24
. TGF-β regulates 
epithelial homeostasis and angiogenesis, thus has been found to be a stimulating factor for 
tumor invasion and metastasis
25
.  Previous studies have shown these growth factors affect 
gene expression in primary and metastatic HNSCC cells differently and could contribute to 
invasive properties of metastatic cells
3
.   
The epidermal growth factor receptor (EGFR) is a transmembrane receptor with 
multiple polypeptide ligands, including growth factors such as EGF and TNF-α.  Ligand 
binding leads to dimerization of the receptor and activation of downstream signaling 
pathways leading to altered gene expression, cellular proliferation, angiogenesis, and 
inhibition of apoptosis, which contribute to the development of malignancies
26
. Increased 
activation of EGFR due to high expression of ligands, or receptor overexpression, has been 
seen in HNSCC
2
.  Stimulation of EGFR pathways has been shown to contribute to tumor 
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cell metastasis.  EGFR activation also stimulates vascular EGF, a protein that stimulates 
vasculogenesis and angiogenesis
26
.  Altered expression, stimulation, and regulation of 
EGFR has been implicated in tumor cell proliferation and motility
27
.  
 
1.7 Epidermal Growth Factor Receptor Pathway Substrate 8 (EPS8) 
EGFR pathway substrate 8 (EPS8) is a downstream mediator of EGFR. EPS8 has 
been found to be an oncoprotein linked to tumor formation.  In nude mice xenografts, 
attenuation of EPS8 has been found to lead to a reduction in tumor formation and 
overexpression has been found to promote tumor growth
28
.  Altered expression of EPS8 
has been found in a variety of human cancers.  In colon cancer, a positive correlation has 
been found between EPS8 overexpression and mitogenesis
28
.  In oral squamous cell 
carcinoma, the EPS8 gene was found to be overexpressed and upregulation correlated with 
lymph node metastasis
29
.  In HNSCC, decreased levels of EPS8 have been found to impair 
tumorgenicity
27
.   
EPS8 has two isoforms, p97 and p68.  The p97 isoform is well characterized and is 
the only isoform detected in human cancer cells.  Structurally, EPS8 has a distinct PH 
domain, SH3 domain, and a degenerate SH2 domain allowing it to interact with a variety 
of molecules bearing the same domains.  EPS8 has been found to bind directly to EGFR 
through a basic amino acid rich domain interacting with multiple glutamic acid residues on 
EGFR.  Overexpression of EPS8 has been shown to enhance EGF-dependent mitogenesis, 
but the underlying mechanism is still unresolved.
30
 EPS8 expression in HNSCC cells 
parallels expression of matrix metalloprotease 9 (MMP-9), which breaks down 
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extracellular matrix, playing a role in tumor cell invasion, and processes growth factors 
and cytokines
27
. EPS8 has been found to deregulate the FOXM1 transcription factor 
leading to elevated expression of CXC-chemokines.
31
   
 
1.8 Chemokines and Chemokine Receptors 
Chemokines are small, secreted polypeptides that function as chemoattractants in 
the immune response.  They share a conserved secondary structure and common “Greek 
key” supersecondary structure consisting of three antiparallel strands and a fourth β-sheet 
region connected by loops. Chemokines are further divided into four subfamilies based on 
disulfide bridge spacing.  These subfamilies include the CXC subfamily (Figure 4), the CC 
subfamily, the C (or XC) subfamily, and the CX3C subfamily. Chemokines serve as 
ligands and bear an “L” suffix. Functionally, chemokines are classified as either 
“homeostatic,” which are constitutively expressed and function in tissue maintenance, or 
“inflammatory,” which are inducible and involved in recruitment and/or maturation of pro-
inflammatory cells.
32
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Figure 4: Structure of Members of the CXC Family of Chemokines.  Members of this 
family of chemokines share a distinct alpha helix and beta sheet region and function as 
ligands.
33
 
 
Chemokines elicit their response by binding to chemokine receptors.  Chemokine 
receptors belong to the rhodopsin-like class of G-protein-coupled 7-transmembrane (7TM) 
helical domain superfamily.  Ligand-receptor interaction occurs at the 7TM domain, and 
receptor’s N-terminal extracellular tail and extracellular loops also play a role.  
Intracellular signaling occurs through coupling of the receptor to downstream signaling 
cascades
32
.         
Chemokine systems have been found to be altered in cancer.  Many cancer cells 
have been found to overexpress chemokine receptors and metastatic sites overexpress 
chemokines. Due to their role in chemotaxis, chemokines are involved in initiating 
movement of cancer cells.  Chemokines are also involved in autocrine and paracrine loops 
that sustain or promote cancer, and are involved in promoting angiogenesis and 
metastasis
32
. 
 
1.9 CXCL5 
CXCL5 (ENA-78 by older nomenclature) is an epithelial cell-derived neutrophil-
activating peptide that binds to the CXCR2 receptor and is processed by MMP-9 after 
secretion.  CXCL5 has been shown to play a role in a variety of cancers including a 
positive correlation in late stages of gastric cancer
34
.  CXCL5 also has been found to 
function as an angiogenic factor in non-small cell lung cancer 
35
.  CXCL5 expression has 
been found to be altered in metastatic cells in HNSCC
36
.   
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CXCL5 production has been found to contribute to enhanced invasion and 
proliferation in HNSCC
37
 and is also elevated in lung cancer samples containing GOF 
mutant p53, leading to enhanced cell motility
38
. Unpublished data from our lab suggest that 
p63 might be a negative regulator of CXCL5 expression and that mutant p53 could 
enhance CXCL5 expression by inhibiting p63 function.  Additionally, EGF treatment has 
been found to lead to elevated CXCL5 expression in HNSCC cells
3
.  Details about the 
relationship between GOF mutant p53, p63, EPS8 and CXCL5, and in particular the 
effects on EPS8 and CXCL5 promoter activity, are still unknown.  
1.10 Model System 
  For our model system, we used a panel of cell lines isolated from patients with 
HNSCC.  HN4 cells were isolated from a primary tongue tumor and express high levels of 
p63 and low levels of EPS8 and CXCL5.  HN12 cells were isolated from a lymph node 
from the same patient and express low levels of p63 and high levels of EPS8 and CXCL5.  
HN4 and HN12 cells express a truncated p53 protein that is non-functional and can not 
tetramerize.  HN6 cells were isolated from a primary tongue tumor from a patient with 
metastatic HNSCC and express a mutant form of p53 with a single amino acid substitution 
(H179L).  HN13 cells are isolated from a patient with HNSCC and express mutant p53 
with a single amino acid substitution (V173F) and an inframe deletion
8
.   
1.11 Hypothesis 
In this current study, our hypothesis is that GOF mutant p53 enhances expression 
of CXCL5 and other chemokines by deregulating chemokine promoter activity, either in an 
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EPS8-dependent or independent manner, a p63 –dependent or independent manner, or a 
combination thereof (Figure 5).  We have two specific aims to test our hypothesis.   
  
In our first aim, we seek to determine effects of different GOF mp53 and p63 on 
CXCL5 (and EPS8) promoter activity and expression.  Previous data from our lab suggest 
that GOF mp53 enhances EPS8 and CXCL5 expression and p63 inhibits EPS8 and CXCL5 
expression (B.L. Field and W.A.Yeudall, unpublished).   
In our second aim, we seek to determine contribution of GOF mp53 and p63 and 
EPS8 to migration.  Previous studies have shown that GOF mp53 enhances migration of 
cancer cells.
38
 While previous studies have shown that p63 inhibits cell migration in the 
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presence of growth factors in small cell lung carcinoma
39
 , p63’s effects on migration in 
HNSCC have not been well characterized.   EPS8 has been shown to contribute to 
migration in HNSCC
27
, so we suspect if p63 is playing an inhibitory role on the EPS8 
promoter and thus EPS8 expression, p63 may play an inhibitory role on migration in 
HNSCC.   
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Material and Methods 
2.1 Plasmid Preparation  
Plasmids containing the EPS8 promoter driving Guassia Luciferase (EPS8prGluc) 
or Enhanced Green Fluorescent Protein (EPS8prEGFP) and containing resistance to 
puromycin were obtained from GeneCopoeia (Rockville, MD) (Figure 6). A plasmid 
containing the CXCL5 promoter driving Firefly luciferase (CXCL5prFluc) was a generous 
gift from Dr A.C. Keates (Harvard Medical School). A plasmid constitutively expressing 
Renilla Luciferase under the control of Thymidine Kinase promoter (pRL) was obtained 
from Promega Corporation (Madison, WI).  A plasmid containing Firefly Luciferase under 
the control of Herpes Simplex Thymidine Kinase promoter (pGL4.14 HSTK) was a gift 
from Dr. A. Waseem (Queen Mary University of London).  Plasmids containing sequences 
encoding TAp63 (pTAp63) and ΔNp63 (pp63) were gifts from Dr. S. Deb (Dept. of 
Biochemistry, VCU) and Dr. Vyomesh Patel (NIDCR, Bethesda, MD).  An empty vector 
plasmid containing Cytomegalovirus promoter, available in our lab, was used as a negative 
control (pCMV).    
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Plasmid DNA sequences were transformed into competent E. coli bacteria (Bioline) 
and grown overnight in LB broth (10 g/L typtone; 5 g/L yeast extract; 171 mM NaCl; pH 
7.0) supplemented with 50μg/ml ampicillin.  Plasmid DNA was prepared using the Wizard 
Midiprep kit (Promega; Madison, WI) according to the manufacturer’s instructions. 
Cultures were centrifuged at 10,000 x g for 30 minutes at 4
o
C and the supernatant 
discarded. Pelleted cells were resuspended in 3 mL of Resuspension Solution (Promega; 
Madison, WI) by pipetting up and down in order to homogenize the sample.  To the 
resuspended cells, 3 mL of Lysis Solution was added and inverted to mix.  Then, 3 mL of 
Neutralization Solution (Promega; Madison, WI) was added and inverted to mix.  Samples 
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were then centrifuged at 14,000 x g for 15 min at 4
o
C.  The supernatant containing the 
DNA was filtered through gauze into a sterile 15 mL tube. 
Isolated plasmid DNA was resuspended in 10 mL of resin.  Mixture was drawn 
through a minicolumn attached to a vacuum.  Once liquid had passed through, the vacuum 
was released.  The column was washed twice with 15 mL of Column Wash Solution 
containing ethanol.  After the second wash, the column was dried by vacuum for an 
additional 30 seconds after all liquid passed through.  The midicolumn was separated from 
the reservoir and the midicolumn placed into a 1.5 mL microcentrifuge tube.  The tubes 
were centrifuged at 10000 x g for 2 minutes.  The midicolumn was then place a new 1.5 
mL microcentrifuge tube.  To the midicolumn, 300 μL of reheated 70oC water was added 
and then centrifuged at 10000 x g for 2 minutes.  The midicolumn was discarded and 
eluted DNA was centrifuged for an additional 5 minutes at 10000 x g.  Supernatant 
containing DNA was then transferred to a new microcentrifuge tube and stored at 4
o
C.   
 
2.2 siRNA 
Luciferase, p53, and p63 were obtained from Sigma-Aldrich, Inc. (St. Louis, MO) 
and are detailed in Table 1 (below).  Mission siRNA Universal Negative Control 
(catMission siRNA Universal Negative Control (cat. # SIC001) was also purchased from 
Sigma Aldrich (St. Louis, MO). Dried oligonucleotides were resuspended in sterile, 
RNase-free water to a final concentration of 100mM.  
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Target Gene siRNA Sequence 
Luciferase 5’-CAUGUCAUGUGUCACAUCUC[dT][dT]-3’ 
p53 5’-AUGGGCCUCCGGUUCAUGC[dT][dT]-3’ 
p63 5’-AACAGCCAUGCCCAGUAUGUA[dT][dT]-3’ 
Table 1: Target Sequences for siRNA.   
2.3 Cell Culture 
HNSCC cells, including HN4, HN6, HN12, and HN13, were cultured in 
Dulbecco’s Modification of Eagle’s Medium (DMEM) supplemented with 100 units/mL 
penicillin/100 μg/mL streptomycin (Invitrogen; Carlsbad, CA), 1mM sodium pyruvate 
(Mediatech, Inc.; Manassas, VA) and 10% fetal calf serum (ThermoScientific; Asheville, 
NC). Cells were incubated at 37˚C in a humidified atmosphere containing 10% CO2 and 
the medium was changed every 2-3 days.  Cells containing the EPS8prGluc and 
EPS8prEGFP plasmids were maintained in medium supplemented with 1μg/mL 
puromycin (Enzo Life Sciences, Inc.; Farmingdale, NY) 
Before cells could grow to confluency, the medium was aspirated off the plates and 
the cells washed thrice in sterile phosphate buffered saline (PBS, 37
o
C) solution to remove 
any remaining media.  In order to detach cells, 1 mL of 0.1% trypsin (Mediatech Inc.; 
Manassas, VA) was added per 10cm plate and incubated for 10-15 minutes at 37
o
C.  
Detached cells were resuspended into a total volume of 10 mL of media.  Cells were 
typically replated at a 1:10 dilution in order to maintain a culture.  Cell stocks were made 
by transferring resuspended cells into a 15 mL tube and centrifuging at 800 RPM for 5 min 
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at 4
o
C.  Remaining media was aspirated and cells were resuspended in 1 mL of 4
o
C 
Bambanker (Wako Chemicals USA; Richmond, VA).  Resuspended cells were then split 
between two cryovials and stored at -80
o
C.   
 
2.4 Cell Transfections 
Cells were transfected with target DNA or siRNA by nucleofection using Mirus 
Ingenio electroporation solution (Mirus Bio LLC; Madison, WI).  For each transfection, at 
least 1 x 10
6
 cells were used as determined using a Cellometer automated cell counter and 
Cellometer Auto T4 software (Nexelcom Bioscience, LLC.; Lawrence, MA).  Cells were 
centrifuged at 800 RPM for 5 minutes at 4
o
C and the media aspirated off. Cells were then 
resuspended in 100 μL of electroporation solution and 1 μg of each DNA plasmid and/or 
1uL of 100mM siRNA was added.  This solution was then transferred into a 0.2mm 
cuvette and placed into a Nucleofector II machine (Lonza; Allendale, NJ). The T-20 
protocol was used for most transfections; T-007 protocol (high viability) was used when 
transfecting HN4 cells.  Transfected cells were then placed into a 10cm plate of 12 mL pre-
warmed DMEM.  Stable cell lines containing the EPS8prGluc were selected for using 
DMEM supplemented with puromycin (see Cell Culture).  Transiently transfected cells 
were assayed 2-7 days after the initial transfection.   
 
2.5 RNA Isolation 
Medium was aspirated from subconfluent cells grown in six well plates and 1 mL 
of TRIzol (Invitrogen; Carlsbad, CA) was added to each well.  Plates were then incubated 
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for 5 minutes on a shaker in order to homogenize samples.  Samples were then transferred 
into sterile 1.5 mL microcentrifuge tubes and 0.2 mL of chloroform added.  Tubes were 
shaken vigorously for 15 seconds and then incubated at room temperature for 3 minutes.  
Tubes were then centrifuged for 15 minutes at 12,000 x g at 4
o
C in order to separate the 
phenol phase from the RNA-containing aqueous phase.  The aqueous phases were then 
transferred to a sterile microcentrifuge tubes.  RNA was precipitated from the aqueous 
phase by incubating with 0.5 mL of 100% isopropanol for 10 minutes and then centrifuged 
for 10 minutes at 12,000 x g at 4
o
C in order to pellet the RNA.  The supernatant was then 
removed and the RNA pellets were washed with 1 mL of 75% ethanol.  Tubes were then 
centrifuged for 5 minutes at 7,500 x g at 4
o
C and the wash discarded.  The pellets were 
allowed to air dry in an inverted tube for 10 minutes at room temperature.  RNA was then 
resuspended in 30 μL of RNase free water and incubated for 15 minutes in a 60oC water 
bath.  Isolated RNA was then stored at -20
o
C.  RNA concentration was determined using a 
spectrophotometer (Nanodrop; ThermoScientific; Asheville, NC) and ND1000 software.  
 
2.6 Reverse Transcription 
Into a sterile 1.5 mL microcentrifuge tube, 3-5 μg of isolated RNA, 1 μL of 
oligo(dT)18 (0.5μg/μL) (SigmaAldrich, Inc.; St. Louis, MO) and dNTP mix (10mM each) 
(Bioline; Taunton, MA) were added and the volume was brought up to 13 μL using RNase 
free water.  Tubes were heated at 65
o
C for 5 minutes, and then quickly chilled on ice 
before centrifugation for 30 seconds.  To each tube, 4 μL of 5x First-Strand Buffer 
(Invitrogen; Carlsbad, CA) and 2 μL 0.1M DTT (Invitrogen; Carlsbad, CA) were added 
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and mixed gently by pipetting.  Tubes were incubated in a 42
o
C water bath for 2 minutes.  
To each tube, 1 μL of MultiScribe reverse transcriptase (50U/μL) (Applied Biosystems; 
Carlsbad, CA) was added and tubes were incubated for 50 minutes in a 42
o
C water bath.  
To inactivate the reaction, tubes were heated to 70
o
C for 15 minutes and then stored at -
20
o
C.   
 
2.7 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
RNA was isolated, quantified, and reverse transcribed as described above.  For 
each primer, a master mix was made up of 5 μL SYBR Green, 3 μL of RNAse free water, 
and 1 μL target primer per well.  To each well of a fast optical 96-well reaction plate (0.1 
mL) (Applied Biosystems; Carlsbad, CA), 9 μL of master mix was added and 1 μL of 
target DNA was added in triplicate.  As a negative control, 1 μL of water was used as a 
template.  To construct a standard curve for each specific gene target, 1 μL of a serial 
dilution of previous PCR products for each primer set was utilized.  The 96 well plate was 
sealed with an RNase-free optical adhesive film (Applied Biosystems; Carlsbad, CA), and 
then centrifuged for 1 minute at 800 RPM.  The plate was placed into a Fast Real-Time 
PCR System thermal cycler (Applied Biosystems; Carlsbad, CA) and incubated at 50˚C for 
2 minutes then 95˚C for 10 minutes.  Then it was subjected to 40 cycles of 15 seconds 
incubation at 95˚C and 1 minute at 60˚C. 7500 Fast System SDS software was used to 
control the amplification protocol and to conduct analysis of the data.   
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2.8 Agarose Gel Electrophoresis 
For resolving DNA, a 1% gel was made using 1g of agarose powder (Bioline; 
Taunton, MA) added to 100mL of 1X TAE running buffer (40 mM Tris-acetate, 1 mM 
EDTA) The solution was microwaved at 50% power at short intervals and mixed in 
between to avoid overheating.  Into the completely dissolved solution, 0.5μL of ethidium 
bromide solution (10µg/µL) was added and then the solution poured onto a cooled gel tray 
with well comb.   
DNA samples were prepared using 10 μL of PCR product cDNA and 2.5 μL of 5x 
loading buffer (0.25% bromophenol blue, 15% Ficoll 400).  Samples were loaded into 
individual wells and Hyperladder I or II molecular weight markers (BioLine; Taunton, 
MA) was utilized based on size of the DNA fragments to be analyzed.  Gels were 
electrophoresed horizontally for 30-45 minutes at a constant 100V.  Gels were visualized 
using a UV transilluminator at 302nm and imaged using a CCD camera and software 
(Alpha Imager, Alpha InnoTec; Germany).   
 
2.9 Protein Isolation 
Lysis buffer was supplemented with protease inhibitors by adding 5 μL 10mg/mL 
aprotinin, 5 μL 10mg/mL leupeptin, and 5μL 0.1M PMSF into 1 mL of lysis buffer (20 
mM HEPES, pH 7.5; 10 mM EGTA, pH 8.0; 40 mM of β-glycerophosphate; 5mL 1% NP-
40 lysis buffer; and 1.50 mM MgCl2).  Medium was aspirated from six well plates of 
subconfluent cells and then washed twice in ice cold PBS.  To each well, 100 μL of lysis 
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buffer was added and placed on ice for 10 minutes.  Plates were then scraped and the 
suspension was transferred into sterile microcentrifuge tubes. Tubes were centrifuged for 
10 minutes at 10,000 RPM and 4
o
C.  The supernatants of clarified protein lysates were 
then transferred into fresh microcentrifuge tubes and stored at -20
o
C.  
To determine protein concentration, Bradford assay using BioRad Protein Assay 
Solution (Herculues, CA) was conducted on each sample to determine absorbance at 
600nm.  Concentration was then determined using a standard curve fitted for an 
absorbance vs. concentration plot of 50μg/mL, 25μg/mL, 10μg/mL, 5μg/mL, and 1μg/mL 
samples of bovine serum albumin (BSA).   
 
2.10 Polyacrylamide Gel Electrophoresis  
For a 1.5 mm thick mini-gel, a Tris-glycine SDS-polyacrylamide gel (10% 
acrylamide; 0.375 M Tris, pH 8.8; 0.01% sodium dodecyl sulfate (SDS), 0.01% 
ammonium persulfalte (APS), 0.4% Tetramethylethylenediamine (TEMED)) was poured 
with a layer of water on top.  After the resolving gel had set, the water layer was removed 
and a stacking gel (5% acrylamide mix; 0.125 Tris, pH 6.8; 0.01% SDS, 0.01% APS, 1% 
TEMED) was poured on top and a comb inserted.   
Samples were prepared by using 28 μL of the lowest concentrated sample and an 
equivalent microgram amount of all other samples.  Samples were made up to 28 μL using 
lysis buffer and then 7 μL of 5x SDS loading buffer was added.  Samples were heated at 
95
o
C for 10 minutes and then loaded into the gel. Molecular weight controls consisted of 3 
μL of MagicMark XP Western Standard (Invitrogen; Carlsbad, CA), and 3μL of 
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BenchMark Prestained Protein Ladder (Invitrogen; Carlsbad, CA).  Gels were 
electrophoresed at 100 V over 1.5 – 2 hrs in 1X SDS-PAGE running buffer (20mM Tris-
glycine pH 8.3, 2% (w/v) SDS).   
 
2.11 Western Blot Analysis 
A PVDF transfer membrane (Immobilon-P; Millipore Corp.; Bedford, MA) 
membrane was soaked in methanol and then soaked with filter paper and sponges in 1X 
transfer buffer (20mM Tris-HCl pH 7.9, 100mM NaCl, 70mM EDTA, 10% MeOH).  
These components were then layered with the gel and then transferred at 10 mA constant 
current overnight in 1x transfer buffer.   
After overnight transfer, the membrane was dehydrated in methanol and then 
allowed to completely air dry on filter paper.  The dried membrane was then re-wet in 
methanol and then washed for 10 minutes in TBS (10 mM Tris HCl pH 7.6, 150 mM 
NaCl) supplemented with 0.5% Tween 20 (Fisher Bioreagents; Rockville, MD) (T-TBS).  
The membrane was then removed and blocked in 5% milk in 1x T-TBS for at least 1 hour 
on a shaker at room temperature or overnight at 4
o
C.  The membrane was then removed 
and incubated in primary antibody on a shaker for 1 hour at room temperature or overnight 
at 4
o
C.  The membrane was then washed three times at ambient temperature for 10 minutes 
in TTBS.  The membrane was then incubated in animal specific secondary antibody on a 
shaker for 1 hour at ambient temperature.  Anti-goat secondary was obtained from MP 
Biomedical.  Anti-mouse was obtained from Cell Signalling.  The membrane was then 
washed three times for 10 minutes or six times for 5 minutes in TTBS. 
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Primary Antibody Raised Against Dilution Secondary Antibody 
(Dilution) 
actin C-terminus (1:1000) Anti-goat (1:10,000) 
EPS8 aa 628-821 (1:5000) Anti-mouse (1:10,000) 
p53 aa 11-25 (1:1000) Anti-mouse (1:10,000) 
p63 aa 1-205 
(ΔN N-terminus) 
(1:250) Anti-mouse (1:2,000) 
Table 2: Actin (cat. #  IL-6), p53 (cat. # D01), and p63 (cat. # 4A4) antibodies were 
obtained from Santa Cruz Biotechnology (Santa Cruz, CA).  EPS8 antibody (cat. # 
610144) was obtained from BD Biosciences (San Jose, CA).  
 
The membrane was developed with 500 μL each of Western Lightning Oxidizing 
Reagent Plus and Western Lightning Enhanced Luminol Reagent Plus (PerkinElmer Life 
Sciences Inc.; Billerica, MA).  The developing solution was pooled on Saran wrap and the 
membrane placed face down for 3 minutes.  Excess developing solution was squeezed off 
and the membrane imaged using Blue X-ray film (Phenix Research Products; Candler, NC) 
with a Kodak X-OMAT 2000 Processor. 
 
2.12 Luciferase Assay 
Medium was aspirated from a six well plate and wells washed 1x in PBS and 
aspirated.  500 μL of 1x Passive Lysis Buffer, made from the provided 5x solution 
(Promega; Madison, WI) diluted in sterile water, was added to each well.  The plate was 
placed on a shaker for 15 minutes at ambient temperature and then cell lysate and debris 
were scraped into sterile 1.5 mL microcentrifuge tubes.  Tubes were centrifuged for 30 
seconds and the cleared supernatant transferred into sterile microcentrifuge tubes.  Stop 
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and Glo working solution was made for 100 uL per sample by diluting 50x Stop & Glow 
reagent in Stop & Glow Buffer (Promega; Madison, WI).  
In a tube of 100 μL of Luciferase Assay Reagent II (LAR II), 20 μL of sample was 
added and mixed by pipetting up and down.  The sample was then place into a Glomax 
20/20 luminometer (Promega; Madison, WI) where a protocol with 10 second integration 
was run.  After the first reading, 100 μL of Stop and Glo reagent was added and vortexed 
for 15 seconds at 3000 RPM.  The sample was then placed back into the luminometer for a 
second reading.  The individual readings recorded in relative light units (RLU) and ratio of 
the first reading to the second reading .   
Luminometer readings are dependent on luciferase enzymes expressed, which vary 
based on the plasmid construct utilized (Figure 6). Firefly luciferase (FLuc) reacts with 
LAR II and emits within the first reading.  The Stop and Glo reagent quenches this reaction 
and also serves as a substrate for Guassia luciferase (Gluc) and Renilla luciferase (pRL), 
which both emit within the second reading.  Unless a stable cell line is used, these reporter 
plasmids were cotransfected with a normalizing plasmid in order to account for 
transfection efficiency (Table 3).  These normalizing plasmids express constitutively 
expressed luciferase enzymes that react and emit differently than the plasmid containing 
the promoter of interest. 
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Promoter of 
Interest Plasmid 
Cotransfected 
Plasmid 
Reading 1 (RLU1) Reading 2 (RLU2) 
 
CXCL5prFluc 
 
 
pRL 
 
CXCL5pr activity 
(Fluc) 
 
Transfection 
efficiency (pRL) 
 
 
 
EPS8prGluc 
 
pGL4.14 HSTK 
Transfection efficiency  
(pGL4.14 HSTK) 
 
EPS8pr activity 
(Gluc) 
None 
(stable cell line) 
background EPS8pr activity 
(Gluc) 
Table 3: Luciferase Assay.  Depending on promoter construct used, promoter of interest 
activity will be reported at different reading based on substrates for enzymes utilized.  
 
2.13 Statistical Analysis 
Data were analyzed using GraphPad QuickCalcs software 
(http://www.graphpad.com/quickcalcs) to conduct unpaired t-test to compare two means.  
A p value of less than 0.05 was considered statistically significant for this study.   
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Results 
3.1 Creation of stable cell lines  
In order to study EPS8 promoter activity more easily, stable cell lines were created 
by transfecting a plasmid containing the EPS8 promoter driving expression of either 
Guassia Luciferase (EPS8prGluc) or Enhanced Green Fluorescent Protein (EPS8prEGFP), 
in addition to puromycin resistance, into HN4 and HN12 cells.  Such cell lines would 
allow for the study of promoter activity of the plasmid construct without the need to 
cotransfect with another DNA plasmid for normalization.  After transfection of DNA, the 
cells were cultured in media supplemented with puromycin for 10-15 days or until discreet 
colonies became visible.  At the end of this period, protein and luciferase assay samples 
were isolated by the standard protocols (as described above).  
Figure 7A shows a Western blot image of protein samples derived from the 
HN4/EPS8prEGFP and HN4/EPS8prGLuc cell lines, illustrating the expression of EGFP 
in the created HN4/EPS8prEGFP cell line, but not in cells transfected with the luciferase 
plasmid.  Conversely, luciferase assay data from these cell lines shows high activity of the 
EPS8prGluc in HN4 cells as expected (Figure 7B), but not in the EGFP-transfected cells.  
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HN12 derivative cell lines also exhibited high expression of EGFP protein by 
Western blot (HN12/EPS8prEGFP cells, Figure 8A) and high activity of the EPS8prGluc 
construct by luciferase assay (Figure 8B).  These findings confirm the creation of the 
desired stably transfected cell lines.  Similar cell line derivatives were also created using 
HN6 cells by other members of the lab.  
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3.2 Mutant p53 enhances EPS8 and CXCL5 expression and enhances migration  
Previous data from our lab indicated an enhancing role of mutant p53 on EPS8 and 
CXCL5 expression in HNSCC (B.L. Field and W.A.Yeudall, unpublished), which we 
sought to confirm in a different cell line in this study. As seen in Figure 9A, the knock 
down of mutant p53 (H179L) protein in HN6 cells leads to a significant decrease in mRNA 
expression of EPS8 and CXCL5 mRNA (p=0.033 and p=0.01 respectively) (Figure 9B).  
 
Mutant p53 has been shown to contribute to cellular migration
38
, although the 
mechanism is unclear.  Therefore, we tested to see if there was a correlation between 
mutant p53 knockdown, reduced EPS8, reduced CXCL5 and altered motility. As seen in 
Figure 10, in our study the knock down of this mutant p53 protein also leads to a 
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significant decrease in cellular migration as seen in wound closure assay (p=0.0003). This 
is consistent with previous data obtained in lung cancer cells
16
 and implicates mutant p53-
dependent regulation of EPS8, a known mediator of actin reorganization, as a potential 
mechanism to explain the enhanced migration of cancer cells containing mutant p53.  
 
3.3 p63 inhibits EPS8 and CXCL5 expression and cellular migration 
Previous data from our lab indicate an inhibitory role of p63 on CXCL5 expression 
(B.L. Field and W.A.Yeudall, unpublished).  In Figure 11, the knock-down of p63 mRNA 
expression using siRNA leads to a significant increase expression of CXCL5 mRNA 
(p=0.001), consistent with previous findings. In addition, EPS8 levels increased when p63 
expression was repressed by siRNA (Figure 11; p=0.01).  
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Previous studies have provided evidence of mutant p53 inhibiting p63 function, 
thereby promoting cellular invasion in small cell lung cancer cells
22
.  We sought to 
characterize the effect of p63 independent of mutant p53 by utilizing HN4 cells that do not 
express a functional p53. As seen in Figure 12, knock down of p63 in these cells using 
siRNA is associated with enhanced cellular migration.  
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3.4 Mutant p53 enhances EPS8 promoter activity  
Preliminary data from our laboratory indicate that mutant p53 might enhance EPS8 
expression.  In this study, we further characterized this relationship in terms of promoter 
activity.  As seen in Figure 13A, the knock down of mutant p53 protein in HN6 cells is 
achieved using siRNA.  Isolates from the same transfection exhibited a significant decrease 
in EPS8 promoter activity with the loss of mutant p53 protein (p=0.001; Figure 13B).   
 
In a complementary experiment, the knock down of mutant p53 protein using p53 
siRNA was carried out in HN13 cells transiently transfected with the previously described 
EPS8prGluc promoter (Figure 14A).  Isolates from this transfection exhibited a significant 
decrease in EPS8 promoter activity with the loss of mutant p53 (Figure 14B).  This 
provides further evidence of mutant p53’s enhancing role on EPS8 expression and 
identifies increased promoter activity as part of the mechanism.  
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3.5 p63 inhibits EPS8 promoter activity 
To explore the inhibitory role of p63 on EPS8 expression further, we utilized the 
stably transfected HN4/EPS8prGluc cell line created (see above).  As seen in Figure 15A, 
p63 protein expression is reduced efficiently in these cells using siRNA . This loss of p63 
was associated with an increase in EPS8 promoter activity (p=0.03; Fig 15B).  This is 
consistent with our previous expression data indicating an inhibitory role of p63 on EPS8 
expression.  
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A complementary experiment was performed in the HN12/EPS8prGluc cell by 
transfection a control, TAp63 and ΔNp63 plasmids in order to overexpression p63 in these 
cells that typically express a low level of p63.  During initial studies, the overexpression of 
p63 protein was not observed after transfection using pTAp63 and pΔNp63 (Figure 16A).  
Interestingly, p63 probed for by Western blot were all of the same molecular weight, which 
would not be expected if the transfection was successful.  This leads us to believe that the 
p63 might represent ΔNp63α, which is the predominant form in HNSCC17.  In a repeated 
trial, overexpression of ΔNp63 mRNA is seen following the same transfection procedure 
(Figure 16B), but no significant difference is seen in EPS8 promoter activity (Figure 16C).  
This could be due to discrepancies between mRNA and protein levels of p63.     
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3.6 Mutant p53 enhances CXCL5 promoter activity  
In order to characterize mutant p53’s effects on CXCL5 expression further, HN6 
and HN13 cells were transiently transfected with a plasmid containing the CXCL5 
promoter driving expression of Firefly luciferase (CXCL5prFluc), Renilla luciferase 
plasmid, and siRNA.  As seen in Figure 17A, the knockdown of mutant p53 protein was 
achieved in HN6 cells and is associated with a decrease in CXCL5 promoter activity 
(p=0.001; Fig. 17B).  
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In a complementary experiment, the knockdown of mutant p53 was achieved in 
HN13 cells (Fig 18A) and is associated with a decrease in CXCL5 promoter activity 
(p=0.001; Fig 18B).  These findings are consistent with previous data from our lab 
indicating an enhancing role of mutant p53 on CXCL5 expression levels and extends 
previous work by indicating that this is due, at least in part, to increased promoter activity.  
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3.7 p63 inhibits CXCL5 promoter activity  
Previous data from our lab has indicated an inhibitory role of p63 on CXCL5 
expression.  In order to further study p63’s effects onCXCL5 expression, HN4 cells were 
transiently transfected with CXCL5prFluc plasmid, Renilla Luciferase, and siRNA in order 
to study CXCL5 promoter activity.  As seen in Figure 19A, knockdown of p63 protein was 
achieved using siRNA and is associated with an increase in CXCL5 promoter activity 
(Figure 19B).  This provides further evidence of p63’s inhibitory role on CXCL5 
expression and that the effects are manifest through altered promoter activity.    
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Discussion 
 
4.1 GOF Mutant p53 Enhances HNSCC Tumorigenesis 
 Previous findings from our lab illustrate an enhancing role of GOF mutant p53 in 
cellular migration by expressing GOF mutant p53 in HN4 cells
38
.  In this current study, we 
used different cell lines, HN6 and HN13, isolated from HNSCC tumors that express 
endogenous GOF mutant p53.  After delivery of siRNA, we confirmed the knockdown of 
p53 protein in these cell lines using Western Blot.  We observed decreased migration of 
HN6 cells when mutant p53 was inhibited, indicating a role for GOF mutant p53 in cellular 
migration. These findings are consistent with previous studies in non small cell lung cancer 
cells, in which GOF mutant p53 has been found to contribute to cellular migration and 
invasion
22,39
.   
 In HN6 cells, we also observed decreased EPS8 and CXCL5 mRNA levels with the 
loss of mutant p53.  This indicates an enhancing role of GOF mutant p53 on EPS8 and 
CXCL5 expression, which supports previous findings from our lab
38
 (B.L. Field and 
W.A.Yeudall, unpublished). Our study adds further evidence to a possible GOF mutant 
p53-mediated mechanism leading to the overexpression of EPS8 and CXCL5, which have 
been found to contribute to tumorigenesis in HNSCC
27,37
.   
 The enhanced migration associated with GOF mutant p53 could be due to increased 
EPS8 and CXCL5 expression in these cells. In previous studies, the overexpression of 
EPS8 has been found to increase cellular proliferation and migration, but alone was found 
to have no significant effect on invasion
27
.  In our study, the effect of EPS8 and CXCL5 
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overexpression could both be contributing to increased migration. Increased expression of 
EPS8 due to the presence of GOF mutant p53 would effect actin remodeling and increase 
secretion of MMP-9, which contributes to extracellular matrix degradation and processing 
of CXCL5.  Through these pathways, the increased expression of EPS8 due the presence 
of GOF mutant p53 could enhance HNSCC tumorigenesis.  The increased expression of 
EPS8 could be contributing to the increased expression of CXCL5 through the 
upregulation of FOXM1
31
. GOF mutant p53 could also be increasing CXCL5 through an 
EPS8 independent pathway.  The increased expression and secretion of the chemokine due 
to the presence of GOF mutant p53 would establish a more concentrated chemoattractive 
gradient than cells with GOF mutant p53 knocked down.  In HNSCC tumorigenesis, this 
would lead to enhanced migration of endothelial cells for establishment of a tumor blood 
supply in tumor expressing GOF mutant p53.  This proposed mechanism is in line with 
previous studies that have associated the down regulation of CXCL5 with inhibition of 
squamous carcinogenesis
37
.  In order to investigate the mechanism by which GOF mutant 
p53 enhances EPS8 and CXCL5 mRNA expression further, promoter activity of these 
genes was studied.   
 Wild type p53 protein functions as a transcription factor either binding directly to 
promoters of target genes and/or recruiting other transcription factors to target promoters
7
.  
In addition, GOF mutant p53 cell lines have exhibited different transcriptomes than those 
of wild type p53 or even other GOF mutant p53s
15
.  Previous studies in non-small cell lung 
cancer have found GOF mutant p53 down regulates promoters of wild type p53 target 
genes
40,41
.  Thus we suspected that the mutant p53 present in our HNSCC lines may be 
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affecting EPS8 and CXCL5 promoter activity, leading to increased mRNA expression.   
 Our findings identify novel target promoters of GOF mutant p53.  After confirming 
the knockdown of p53 protein using siRNA in HN6 and HN13 cells, we observed a 
significant decrease in EPS8 and CXCL5 promoter activity associated with the loss of 
GOF mutant p53 as determined by luciferase assay. Our findings support our hypothesis of 
an enhancing role of GOF mutant p53 on EPS8 and CXCL5 promoter activity and are 
consistent with our expression studies, thus elucidating further the mechanism in which 
GOF mutant p53 contributes to HNSCC tumor progression.  As a transcription factor, GOF 
mutant p53 can be binding directly to these promoters, or recruiting other transcription 
factors, or a combination of both.  GOF mutant p53 has been found to bind directly to 
DNA leading to altered promoter activity, which would be a mechanism by which GOF 
mutant p53 might be functioning in our study
42
.  Additional experiments need to be 
conducted in order to further elucidate the mechanism by which GOF mutant p53 regulates 
EPS8 and CXCL5 promoter activity.   
 Our current findings support previous studies showing the deregulation of chemokine 
expression in a variety of cancers
43
.  In addition, both EPS8
29
 and CXCL5
37
 
overexpression have been implicated in HNSCC. The elevated promoter activity leading to 
increased mRNA expression of EPS8 and CXCL5 supports the hypothesis that GOF 
mutant p53 proteins play a role in HNSCC tumorigenesis.  
 
4.2 p63 plays an inhibitory role in HNSCC Tumorigenesis 
 Unpublished data from our lab has indicated an inhibitory role of p63 on CXCL5 
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expression, which may be one mechanism by which mutant p53 exerts its effects.  In this 
study, we wanted to characterize p63’s role independent of mutant p53.  As a homolog of 
p53, p63 functions as a transcription factor that binds to consensus DNA sequences on 
target promoters
17
.  Thus we sought to characterize the effects of p63 on promoter activity 
of two possible target genes, EPS8 and CXCL5. Previous studies from our lab have shown 
EGF treatment of HNSCC cells leads to high expression of CXCL5 (B.L. Field and 
W.A.Yeudall, unpublished), though it unknown if this effect is mediated by EPS8, which 
has been shown to increase CXCL5 expression through FOXM1
31
.  
 In order to study p63’s role in HNSCC, we utilized HN4 and HN12 cells from 
HNSCC patients, which express high and low levels of p63, respectively.  In addition, 
these cell lines express a truncated p53 protein, which is non functional and unable to 
oligomerize with p53 or p63.  First, we studied p63’s effects on EPS8 and CXCL5 
expression.  We knocked down p63 in HN4 cells using siRNA, which resulted in increased 
mRNA expression of EPS8 and CXCL5.  Previous studies have independently associated 
the loss of p63
18
 and the overexpression of EPS8
27
 and CXCL5
37
 to HNSCC, but none 
have directly linked p63 to EPS8 and CXCL5 expression.  We also observed increased 
cellular migration with the loss of p63.  A previous study utilized cells from a 
hypopharyngeal tumor from a patient with HNSCC and found both the upregulation and 
downregulation of 127 genes due to the loss of p63.  Of these affected genes, 20% were 
related to cell motility and p63 was found to bind directly to the promoters of a select few, 
indicating a role of p63 in cellular motility and invasion
23
, which coincides with our 
findings.  The inhibitory role of p63 on these target genes expression could contribute 
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impaired HNSCC tumorigenesis, since both EPS8 and CXCL5 overexpression has been 
shown in HNSCC. Based on these findings and previous studies, we believe that p63 could 
be exerting its effects by altering the activity of target gene promoters .     
 In order to study the mechanism by which p63 affects EPS8 and CXCL5 mRNA 
expression levels further, we studied their promoter activities by luciferase assay.  In 
parallel experiments, we observed increased EPS8 and CXCL5 promoter activity 
associated with the loss of p63 protein as confirmed by Western Blot.  These findings 
coincide with previous studies in which p63 was found to alter gene expression of a large 
array of genes and was found to bind directly to several promoters directly
42
.  It is 
important to note that the p63 probed for by Western Blot was observed at an approximate 
molecular weight of 70 kDa, indicating ΔNp63α.  This is consistent with previous findings 
that have shown this isoform to be the predominant form in HNSCC
20
.  Since these 
experiments were conducted in HN4 cells, p63 present must be functioning independent of 
p53, since the p53 present is non functional and truncated preventing oligermerization.  
 Our findings support those of a previous study in which ΔNp63α was found to be a 
negative regulator of promoter activity of several gene targets of wild type p53, including 
p21 and 14-3-3σ, by binding directly to their promoters44.  While previous studies from our 
lab have shown decreased expression of CXCL5 due to GOF mutant p53’s inhibition of 
p63 function, our current findings indicate a new role and mechanism of action for p63 
independent of mutant p53 in HNSCC (B.L. Field and W.A.Yeudall, unpublished).  
 Additional studies to overexpress p63 protein in HN12/EPS8prGluc cells were 
attempted.  During initial experiments, overexpression of p63 protein was not observed by 
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Western blotting after transfection with plasmids containing isoforms of p63.  In one trial, 
overexpression of p63 mRNA was achieved by the same DNA transfection procedure, but 
no significant effect was observed on EPS8 promoter activity, nor was an increased level 
of p63 protein detectable by Western blotting.  These findings could be due to different 
p63 mRNA and protein levels after transfection during this trial.  Future studies comparing 
mRNA and protein levels of p63 and their effects on target promoter activity should be 
conducted in order to resolve this question.   
4.3 Limitations of Current Study 
 In this study, we relied on in vitro models using cell lines derived from HNSCC 
patients.  Since cells were grown in an isolated culture dish with controlled media, the 
model is not entirely representative of the human body, where tumor cells have a more 
complex and dynamic microenviroment.   Tumor cells within the body respond to a variety 
of signaling factors released by other cells.  This is an important aspect of tumor cell 
progression and metastasis, but is lost when in the cell culture procedure used in our study.  
 Scratch assay studies were useful in studying cellular migration across a two 
dimensional surface, but this is not necessarily representative of cellular migration that 
occurs in three dimensions within the body. Other migration assays, such as transwell 
migration assay (see below), could provide more insight into cellular migration in HNSCC.  
 
4.4 Future Studies 
These experiments should be repeated in HNSCC cell lines derived from metastasis 
sites, particularly lymph nodes of the head and neck, which are the primary site of HNSCC 
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metastasis.  Previous studies have shown primary and metastasis sites having varying gene 
expression profiles in HNSCC
3
.  As transcription factors, GOF mutant p53 and p63 could 
be contributing to the varying transcription of genes under their regulation in different 
tumor sites.   
To study cellular migration in a more representative model, transwell migration 
assays, which have been used with other cell lines derived from HNSCC cells, could be 
utilized
38
.  These assays would also allow the study of the effects of chemoattracts and 
growth factors on tumor cell migration, in particular CXCL5, which our studies have 
shown is overexpressed in HNSCC.   In addition, migration across a 3D matrix, such as 
Matrigel, should be conducted in order to study migration in three dimensions.   
In order to study GOF mutant p53 and p63 proteins’ effects on the EPS8 and 
CXCL5 promoters, protein-DNA binding studies such as ChIP assays could be conducted.  
This assay would allow us to investigate if GOF mutant p53 and p63 are acting directly 
through binding to these target promoters or if they are functioning through recruitment of 
other transcription factors.   
In addition, the role of p73 in EPS8 and CXCL5 regulation in HNSCC should also 
be studied.  p73, like p63, can be transcribed form two different promoters lead to TAp73 
and ΔNp73.   ΔNp73 has been found to be the predominating form in HNSCC, while 
TAp73 transcript alteration have been found in HNSCC
45
.  Like other members of its 
family, p73 could be affecting gene expression by deregulation of target promoters in 
HNSCC.    
4.5 Conclusions 
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In this study, we were able to identify new relationships between GOF mutant p53, 
p63, EPS8 and CXCL5 in HNSCC (Figure 20).  We found that GOF mutant p53 enhances 
EPS8 and CXCL5 expression by upregulating promoter activity of these genes.  We also 
found that p63 inhibits EPS8 and CXCL5 expression, independent of GOF mutant p53, 
and does so by decreasing promoter activity.  By further elucidating the mechanism of 
action of these key molecules in HNSCC, therapies targeted at GOF mutant p53 or even 
CXCL5 could be developed to fight tumor development and progression in HNSCC. 
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